Growth Investors & VC Firms in Denmark

76 firms in this list, with a median first check of $2.2M. 26 of them lead rounds. Generated from verified public data and updated continuously.

Fund	FoxScore	HQ	Invests	Stage	Check	CRM
IN Inventure Capital	88🔒	Aarhus	DK	Seed–Growth	—	+ Add to CRM
3I 3i Group SBACAPAK136 people	88🔒	London	GB	Growth–Late Stage	—	+ Add to CRM
TR Triton Partners PPAPATAK105 people	88🔒	London	GB	Seed–Growth	—	+ Add to CRM
NO Northzone BSEPPPSM40 people · Leads rounds	88🔒	London	GB	Seed–Growth	$1M – $50M	+ Add to CRM
MO Monterro Growth LSPLTBSN79 people · Leads rounds	88🔒	Stockholm	SE	Growth	—	+ Add to CRM
EQ EQT Life Sciences MKPFAPBJ59 people · Leads rounds	88🔒	Amsterdam	NL	Seed–Late Stage	$11M – $66M	+ Add to CRM
SE Sev.en Global Investments ASDHDZJK69 people · Leads rounds	88🔒	Prague	CZ	Growth–Late Stage	$540M – $1B	+ Add to CRM
SE Seventure Partners IDBRDMEF19 people · Leads rounds	88🔒	Paris	FR	Seed–Growth	—	+ Add to CRM
GI Giant Ventures Global Llp BEGAHTMA32 people · Leads rounds	88🔒	London	GB	Pre-Seed–Growth	$10M – $20M	+ Add to CRM
HE HealthCap AVAFBOCK33 people	88🔒	Stockholm	SE	Seed–Growth	—	+ Add to CRM
EU Eurazeo CBWKLGLM35 people	88🔒	Paris	FR	Seed–Late Stage	—	+ Add to CRM
BA BaltCap DDKCKKMK23 people	88🔒	Tallinn	EE	Growth	$5.4M – $21.6M	+ Add to CRM
PR Procuritas JCMFDSEF32 people · Leads rounds	88🔒	Stockholm	SE	Growth	—	+ Add to CRM
ID IDC Ventures ABDPLSRL42 people · Leads rounds	88🔒	Miami	US	Pre-Seed–Growth	—	+ Add to CRM
VI Viola Credit IVAGCSEF41 people · Follows rounds	88🔒	Tel Aviv	IL	Growth–Late Stage	—	+ Add to CRM
YS Ysios Capital JPPKAUCG26 people · Follows rounds	88🔒	Barcelona	ES	Seed–Growth	$5.4M – $21.6M	+ Add to CRM
MC McWin Capital Partners HMSKHGMD32 people	88🔒	London	GB	Series B–Growth	—	+ Add to CRM
GI Gilde Healthcare AFEDGPHD26 people · Follows rounds	88🔒	Utrecht	NL	Seed–Late Stage	$1.1M – $55M	+ Add to CRM
ET ETF Partners PSPHFBRD25 people	88🔒	London	GB	Series A–Growth	$5.4M – $16.2M	+ Add to CRM
EV EV Private Equity HTOMMSRJ15 people	88🔒	Stavanger	NO	Growth	$5M – $30M	+ Add to CRM
EU European Circular Bioeconomy Fund DSILMAMB23 people	88🔒	Bonn	DE	Series A–Growth	$5.5M – $16.5M	+ Add to CRM
EE eEquity AB AJCOEMHJ16 people · Leads rounds	88🔒	Stockholm	SE	Series A–Late Stage	$5.4M – $21.6M	+ Add to CRM
CA CapMan HHJHDJIM19 people	88🔒	Helsinki	FI	Growth–Late Stage	$2.2M – $64.8M	+ Add to CRM
CO Cottonwood Technology Fund ALDBLRPC11 people · Leads rounds	88🔒	Denver	US	Pre-Seed–Growth	$1M – $25M	+ Add to CRM

Inventure Capital

AarhusSeed–Growth

3i Group

LondonGrowth–Late Stage

SBACAPAK136 people

Triton Partners

LondonSeed–Growth

PPAPATAK105 people

Northzone

LondonSeed–Growth$1M – $50M

BSEPPPSM40 people

Monterro Growth

StockholmGrowth

LSPLTBSN79 people

EQT Life Sciences

AmsterdamSeed–Late Stage$11M – $66M

MKPFAPBJ59 people

Sev.en Global Investments

PragueGrowth–Late Stage$540M – $1B

ASDHDZJK69 people

Seventure Partners

ParisSeed–Growth

IDBRDMEF19 people

Giant Ventures Global Llp

LondonPre-Seed–Growth$10M – $20M

BEGAHTMA32 people

HealthCap

StockholmSeed–Growth

AVAFBOCK33 people

Eurazeo

ParisSeed–Late Stage

CBWKLGLM35 people

BaltCap

TallinnGrowth$5.4M – $21.6M

DDKCKKMK23 people

Procuritas

StockholmGrowth

JCMFDSEF32 people

IDC Ventures

MiamiPre-Seed–Growth

ABDPLSRL42 people

Viola Credit

Tel AvivGrowth–Late Stage

IVAGCSEF41 people

Ysios Capital

BarcelonaSeed–Growth$5.4M – $21.6M

JPPKAUCG26 people

McWin Capital Partners

LondonSeries B–Growth

HMSKHGMD32 people

Gilde Healthcare

UtrechtSeed–Late Stage$1.1M – $55M

AFEDGPHD26 people

ETF Partners

LondonSeries A–Growth$5.4M – $16.2M

PSPHFBRD25 people

EV Private Equity

StavangerGrowth$5M – $30M

HTOMMSRJ15 people

European Circular Bioeconomy Fund

BonnSeries A–Growth$5.5M – $16.5M

DSILMAMB23 people

eEquity AB

StockholmSeries A–Late Stage$5.4M – $21.6M

AJCOEMHJ16 people

CapMan

HelsinkiGrowth–Late Stage$2.2M – $64.8M

HHJHDJIM19 people

Cottonwood Technology Fund

DenverPre-Seed–Growth$1M – $25M

ALDBLRPC11 people

Data sourced from public filings and firms' own websites — see our methodology.